Enviar búsqueda
Cargar
Pharmacoeconomics1
•
Descargar como PPT, PDF
•
11 recomendaciones
•
1,644 vistas
J
jinender16
Seguir
Denunciar
Compartir
Denunciar
Compartir
1 de 27
Descargar ahora
Recomendados
a comprehensive and detailed about Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Sultan Alharbi
pharmacoeconomics in detail.
Pharmacoeconomics ii
Pharmacoeconomics ii
AakankshaPriya1
ADR
Adverse drug reactions
Adverse drug reactions
Jannatul Ferdoush
PRINCIPLES AND DIFFERENT METHODS
Pharmacoeconomics
Pharmacoeconomics
Santhi Dasari
Introduction To Pharmacoeconomics, Objectives, Need of Pharmacoecomics, Four methods of Pharmaeconomics Evaluation, Basic Terminology, Importance of Pharmacoeconomics.
Pharmacoeconomics
Pharmacoeconomics
Monika P. Maske
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another. By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
Pharmacoeconomics
Pharmacoeconomics
Naina Mohamed, PhD
Pharmacoeconomics by Shagufta Farooqui
Pharmacoeconomics
Pharmacoeconomics
Shagufta Farooqui
pharmacoeconomics, cost of drugs , how to analyse the cost and the outcome
Pharmacoeconomics
Pharmacoeconomics
Dr VARUN RAGHAVAN
Recomendados
a comprehensive and detailed about Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Sultan Alharbi
pharmacoeconomics in detail.
Pharmacoeconomics ii
Pharmacoeconomics ii
AakankshaPriya1
ADR
Adverse drug reactions
Adverse drug reactions
Jannatul Ferdoush
PRINCIPLES AND DIFFERENT METHODS
Pharmacoeconomics
Pharmacoeconomics
Santhi Dasari
Introduction To Pharmacoeconomics, Objectives, Need of Pharmacoecomics, Four methods of Pharmaeconomics Evaluation, Basic Terminology, Importance of Pharmacoeconomics.
Pharmacoeconomics
Pharmacoeconomics
Monika P. Maske
Pharmacoeconomics is a branch of health economics which compares the value of one drug or a drug therapy to another. By understanding the principles, methods, and application of pharmacoeconomics, healthcare professionals will be prepared to make better decisions regarding the use of pharmaceutical products and services.
Pharmacoeconomics
Pharmacoeconomics
Naina Mohamed, PhD
Pharmacoeconomics by Shagufta Farooqui
Pharmacoeconomics
Pharmacoeconomics
Shagufta Farooqui
pharmacoeconomics, cost of drugs , how to analyse the cost and the outcome
Pharmacoeconomics
Pharmacoeconomics
Dr VARUN RAGHAVAN
PHARMACOECONOMICS, definition, prospectives, method of study, application
Pharmacoeconomics
Pharmacoeconomics
Asma Ashraf
basics of pharmacoeconomics
Pharmacoeconomics by harsh
Pharmacoeconomics by harsh
Harsh Yadav
It's the study of health economics.
Seminar pharmacoeconomics
Seminar pharmacoeconomics
SameerKhasbage
Pharmacoeconomic methods along with its advantages and disadvantages are described briefly.
Pharmacoeconomics methods & its issues
Pharmacoeconomics methods & its issues
Ganeshprabu10
A concise overview of pharmacoeconomics, health economics, various costs, various pharmacoeconomic study designs and its application in the field of medicine and drug development
Pharmacoeconomics
Pharmacoeconomics
Dr. Siddhartha Dutta
Pharmaconomics
Pharmaconomics
USmile Ï Ṩṃïlệ
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Tulasi Raman
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Zainab&Sons
Pharmacoeconomics introduction methodologies perspectives
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
Dr Roohana Hasan
breast cancer
breast cancer pharmacotherapy
breast cancer pharmacotherapy
Sugunapharmd
Vaccine safety monitoring is a critical aspect of pharmacovigilance, particularly given the widespread use of vaccines to prevent infectious diseases. Robust surveillance systems are essential to detect and assess any potential adverse events following vaccination. Here are some key pharmacovigilance strategies employed for vaccine safety monitoring: Passive Surveillance Systems: Passive surveillance systems rely on healthcare providers, patients, and other stakeholders to voluntarily report adverse events following vaccination. These reports are collected in databases such as the Vaccine Adverse Event Reporting System (VAERS) in the United States or the Vaccine Adverse Event Surveillance System (VAESS) in other countries. While these systems are valuable for signal detection, they may suffer from underreporting and reporting bias. Active Surveillance Systems: Active surveillance involves proactively monitoring a defined population for adverse events following vaccination. This can be done through electronic health records (EHRs), claims databases, and other health data sources. The Vaccine Safety Datalink (VSD) in the United States is an example of an active surveillance system that uses large databases to continuously monitor vaccine safety. Enhanced Surveillance and Cohort Studies: Enhanced surveillance involves more intensive monitoring of a specific population or group of interest. Cohort studies are prospective studies that follow a group of vaccinated individuals over time to assess vaccine safety. These studies provide more detailed and controlled data compared to passive or active surveillance. Comparative Effectiveness Research: Comparative effectiveness research compares the safety of different vaccines or vaccination schedules. By analyzing large datasets, researchers can evaluate the relative risks and benefits of vaccines and identify any safety concerns. Signal Detection and Analysis: Data mining and statistical techniques are used to identify potential safety signals from adverse event reports. Signals are further investigated through in-depth analysis to determine if there is a causal relationship between the vaccine and the adverse event. Causality Assessment: Similar to general pharmacovigilance, causality assessment methods (such as the Naranjo Algorithm, WHO-UMC System, and Bayesian methods) are used to evaluate the likelihood of a causal relationship between a vaccine and an adverse event. Risk Communication and Public Awareness: Effective communication strategies are crucial to ensure that healthcare providers and the public are informed about vaccine safety. This involves providing clear and accurate information about potential risks and benefits.
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
ClinosolIndia
Quality Use of Medicines means: • Selecting management options wisely by: Considering the place of medicines in treating illness and maintaining health, and recognising that there may be better ways than medicine to manage many disorders. • Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account: - the individual - the clinical condition - risks and benefits - dosage and length of treatment - any co-existing conditions - other therapies - monitoring considerations - costs for the individual, the community and the health system as a whole.
Quality use medicine
Quality use medicine
FARAZULHODA
ADR
ADR AND ITS MONITORING
ADR AND ITS MONITORING
abhishek mondal
Crp
basic information resource.pptx
basic information resource.pptx
SiddharthShekharSing4
Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
Pharmacoeconomics pptx
Pharmacoeconomics pptx
VishwasATL
Pharmacoeconomics is the one of the evolving area in Clinical pharmacy. Let's go through the history of PE and need of PE in India.
INTRODUCTION TO PHARMACOECONOMICS.pptx
INTRODUCTION TO PHARMACOECONOMICS.pptx
Ameena Kadar
Cost minimisation analysis in health economics
Cost minimisation analysis in health economics
a01071979
In this presentation I have tried to explain in brief about Genetic polymorphism in drug metabolism.
Genetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolism
Dr. Ankit Gaur
pharmacogenetic
Pharmacogenetics
Pharmacogenetics
vipin999
Mohammed A Mohammed. Pharmacoeconomics: Cost utility analysis. Sept 2013
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
Mohammed Mohammed
about phamacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Sanghmitra Priyadarshini
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSA
Stevce Acevski
Más contenido relacionado
La actualidad más candente
PHARMACOECONOMICS, definition, prospectives, method of study, application
Pharmacoeconomics
Pharmacoeconomics
Asma Ashraf
basics of pharmacoeconomics
Pharmacoeconomics by harsh
Pharmacoeconomics by harsh
Harsh Yadav
It's the study of health economics.
Seminar pharmacoeconomics
Seminar pharmacoeconomics
SameerKhasbage
Pharmacoeconomic methods along with its advantages and disadvantages are described briefly.
Pharmacoeconomics methods & its issues
Pharmacoeconomics methods & its issues
Ganeshprabu10
A concise overview of pharmacoeconomics, health economics, various costs, various pharmacoeconomic study designs and its application in the field of medicine and drug development
Pharmacoeconomics
Pharmacoeconomics
Dr. Siddhartha Dutta
Pharmaconomics
Pharmaconomics
USmile Ï Ṩṃïlệ
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Tulasi Raman
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Zainab&Sons
Pharmacoeconomics introduction methodologies perspectives
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
Dr Roohana Hasan
breast cancer
breast cancer pharmacotherapy
breast cancer pharmacotherapy
Sugunapharmd
Vaccine safety monitoring is a critical aspect of pharmacovigilance, particularly given the widespread use of vaccines to prevent infectious diseases. Robust surveillance systems are essential to detect and assess any potential adverse events following vaccination. Here are some key pharmacovigilance strategies employed for vaccine safety monitoring: Passive Surveillance Systems: Passive surveillance systems rely on healthcare providers, patients, and other stakeholders to voluntarily report adverse events following vaccination. These reports are collected in databases such as the Vaccine Adverse Event Reporting System (VAERS) in the United States or the Vaccine Adverse Event Surveillance System (VAESS) in other countries. While these systems are valuable for signal detection, they may suffer from underreporting and reporting bias. Active Surveillance Systems: Active surveillance involves proactively monitoring a defined population for adverse events following vaccination. This can be done through electronic health records (EHRs), claims databases, and other health data sources. The Vaccine Safety Datalink (VSD) in the United States is an example of an active surveillance system that uses large databases to continuously monitor vaccine safety. Enhanced Surveillance and Cohort Studies: Enhanced surveillance involves more intensive monitoring of a specific population or group of interest. Cohort studies are prospective studies that follow a group of vaccinated individuals over time to assess vaccine safety. These studies provide more detailed and controlled data compared to passive or active surveillance. Comparative Effectiveness Research: Comparative effectiveness research compares the safety of different vaccines or vaccination schedules. By analyzing large datasets, researchers can evaluate the relative risks and benefits of vaccines and identify any safety concerns. Signal Detection and Analysis: Data mining and statistical techniques are used to identify potential safety signals from adverse event reports. Signals are further investigated through in-depth analysis to determine if there is a causal relationship between the vaccine and the adverse event. Causality Assessment: Similar to general pharmacovigilance, causality assessment methods (such as the Naranjo Algorithm, WHO-UMC System, and Bayesian methods) are used to evaluate the likelihood of a causal relationship between a vaccine and an adverse event. Risk Communication and Public Awareness: Effective communication strategies are crucial to ensure that healthcare providers and the public are informed about vaccine safety. This involves providing clear and accurate information about potential risks and benefits.
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
ClinosolIndia
Quality Use of Medicines means: • Selecting management options wisely by: Considering the place of medicines in treating illness and maintaining health, and recognising that there may be better ways than medicine to manage many disorders. • Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account: - the individual - the clinical condition - risks and benefits - dosage and length of treatment - any co-existing conditions - other therapies - monitoring considerations - costs for the individual, the community and the health system as a whole.
Quality use medicine
Quality use medicine
FARAZULHODA
ADR
ADR AND ITS MONITORING
ADR AND ITS MONITORING
abhishek mondal
Crp
basic information resource.pptx
basic information resource.pptx
SiddharthShekharSing4
Pharmacoeconomics is essential to reduce burden for patients in the terms of cost and improve the therapeutic effectiveness by selecting alternative treatments. Physician and pharmacist plays an important role in selecting drugs and treatment alternatives. So, proper selection helps to minimize the cost of therapy in patients. Research studies on pharmacoeconomics helps to know the burden of patients paying for their illness.
Pharmacoeconomics pptx
Pharmacoeconomics pptx
VishwasATL
Pharmacoeconomics is the one of the evolving area in Clinical pharmacy. Let's go through the history of PE and need of PE in India.
INTRODUCTION TO PHARMACOECONOMICS.pptx
INTRODUCTION TO PHARMACOECONOMICS.pptx
Ameena Kadar
Cost minimisation analysis in health economics
Cost minimisation analysis in health economics
a01071979
In this presentation I have tried to explain in brief about Genetic polymorphism in drug metabolism.
Genetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolism
Dr. Ankit Gaur
pharmacogenetic
Pharmacogenetics
Pharmacogenetics
vipin999
Mohammed A Mohammed. Pharmacoeconomics: Cost utility analysis. Sept 2013
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
Mohammed Mohammed
La actualidad más candente
(20)
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics by harsh
Pharmacoeconomics by harsh
Seminar pharmacoeconomics
Seminar pharmacoeconomics
Pharmacoeconomics methods & its issues
Pharmacoeconomics methods & its issues
Pharmacoeconomics
Pharmacoeconomics
Pharmaconomics
Pharmaconomics
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
breast cancer pharmacotherapy
breast cancer pharmacotherapy
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Vaccine Safety Monitoring: Pharmacovigilance Strategies
Quality use medicine
Quality use medicine
ADR AND ITS MONITORING
ADR AND ITS MONITORING
basic information resource.pptx
basic information resource.pptx
Pharmacoeconomics pptx
Pharmacoeconomics pptx
INTRODUCTION TO PHARMACOECONOMICS.pptx
INTRODUCTION TO PHARMACOECONOMICS.pptx
Cost minimisation analysis in health economics
Cost minimisation analysis in health economics
Genetic polymorphism in drug metabolism
Genetic polymorphism in drug metabolism
Pharmacogenetics
Pharmacogenetics
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
Destacado
about phamacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Sanghmitra Priyadarshini
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSA
Stevce Acevski
PG activity seminar for JR1
Pharmacoeconomics seminar
Pharmacoeconomics seminar
Dr Ketan Asawalle
A beginner's guide to understanding what pharmacoeconomics is all about!!!!
Intro to pharmacoeconomics
Intro to pharmacoeconomics
samthamby79
2nd Annual Health Outcomes and Pharmacoeconomics Research Conference • Setting up internal processes to ensure proper Health Technology Assessment (HTA) • Exploring initiatives to translate reported outcomes to ensure proper understanding of data • Assessing the key HTA entities in the U.S. and establishing assessment protocol • Differentiating HTA strategies with new technology assessment strategies to improve assessment processes
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
bpstat
This is the summary of a webinar I delivered in November 2012 on Health Outcomes Liaisons and their roles in supporting managed care busines and ACO business.
Hol webinar summary
Hol webinar summary
Cameron Tew
Establishes Pharmacoeconomic specialist pharmacist program
Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1
Noura Aljohani
This presentation will help you understand the value of Pharmacoeconomic Assessment.
Pharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and Beyond
Medpace
How to demonstrate the value of one drug compared to the other
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)
Arlen Meyers, MD, MBA
Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)
jonblanck
The OECD is a leading organization in the international measurement of health system performance. The OECD Expert Group on Health Care Quality Indicators (HCQI) has recently revised its performance framework, identifying core indicators and highlighting new directions. Although improving, the capacity of countries to deliver more accurate standardized indicators still needs to be fostered. A particular aspect that deserves attention is the design, planning and implementation of public performance reporting. Such activity, strictly interrelated to the capacity of the information infrastructure, also depends from cultural, organizational and political conditions that can be differently present at the international level. The applicability of standardized principles and the evidence of improved outcomes due to public reporting systems is still questioned to a large extent. A first international conference on the topic of hospital performance reporting has been organized in Rome, Italy in 2014, followed by a second event held in Seoul, South Korea, in 2015. In his talk, Fabrizio Carinci will present recent developments of OECD projects, including: • state of the art in the definition of OECD performance indicators • challenges emerging from OECD R&D studies • transferability and use of definitions at sub-national and provider level • applicability for hospital performance benchmarking and geographical variation • limitations imposed by the legislation on privacy and data protection • an overarching vision of “essential levels of health information” Through practical examples drawn from his direct experience as Member of the Bureau of the HCQI and other relevant Boards, Prof. Fabrizio Carinci will discuss the state of the art, the role played by national governments (including Australia), and potential avenues for mutual collaboration.
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...
Sax Institute
Methods and practical applications in health technology assessment / pharmacoeconomics
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016
ipposi
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Dr.Sohel Memon
pharmaco-economics and drug compliance
Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance
Naser Tadvi
An introduction to the aspects of the new field of pharmacoepidemiology
Pharmacoepidemiology
Pharmacoepidemiology
Divjyot Kaur
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
guestd708a83
www.interlinkconsultancy.com Healthcare industry challenges and pharmacoeconomic solutions.The pharma industry product pipelines are drying up, leading to a high dependence on existing products for survival. The branded generic drugs segment has become commoditized due to ever increasing and fierce competition.Price plays a major role in drug prescription and buying decisions. High price may not always assure high quality or more benefits and companies are finding it difficult to substantiate higher prices..
Pharmacoeconomics
Pharmacoeconomics
CLARAsteven7
Neoplasia Etiology and pathogenesis of cancer
Neoplasia Etiology and pathogenesis of cancer
Subramani Parasuraman
A step-by-step guide on producing brilliant slide-decks - that are really easy to do. See www.thewikiman.org for more stuff.
5 easy ways to create fabulous slides
5 easy ways to create fabulous slides
Ned Potter
Pharmacoepidemiology
Pharmacoepidemiology
Govind Girase
Destacado
(20)
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomics seminar
Pharmacoeconomics seminar
Intro to pharmacoeconomics
Intro to pharmacoeconomics
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Hol webinar summary
Hol webinar summary
Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1
Pharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and Beyond
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)
Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance
Pharmacoepidemiology
Pharmacoepidemiology
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Pharmacoeconomics
Pharmacoeconomics
Neoplasia Etiology and pathogenesis of cancer
Neoplasia Etiology and pathogenesis of cancer
5 easy ways to create fabulous slides
5 easy ways to create fabulous slides
Pharmacoepidemiology
Pharmacoepidemiology
Similar a Pharmacoeconomics1
Pharmacoeconomics can be regarded as a branch of health economics which deals with identifying, measuring, and comparing the costs and consequences of pharmaceutical products and services. Some of the concepts involved in pharmacoeconomic analysis include cost minimization, cost effectiveness, cost benefit, and cost utility analysis.
Outcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomics
Dureshahwar khan
brief on pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Ijeh Cyril
Pharmacoeconomics1
Pharmacoeconomics1
jinender16
Pharmaconomics
Pharmaconomics
USmile Ï Ṩṃïlệ
Pharmacoeconomics
Pharmacoeconomics.ppt
Pharmacoeconomics.ppt
Pabitra Thapa
yashmaru987@gmail.com
Pharmacoeconomics STUDY
Pharmacoeconomics STUDY
Suvarta Maru
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Zainab&Sons
pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
DrRenuYadav2
pharmacoeconomics
Pharmacoeconomics ppt.
Pharmacoeconomics ppt.
shahvijita
A short seminar on Pharmacoeconomics for post graduate students in Pharmacology
Pharmacoeconomics
Pharmacoeconomics
Dr.Kavitha Vivek
Social Pharmacy
PHARMACOECONOMICS.pptx
PHARMACOECONOMICS.pptx
KLE COLLEGE OF PHARMACY
PHARMACOVIGILANCE
Pharmacoeconomis
Pharmacoeconomis
aanchalarya4
M PHARM
Pharmacoeconomis
Pharmacoeconomis
Aanchal46
Detail description regarding pharmacoeconomics, Cost benefit, cost utility, cost effective and cost minimal analysis
Pharmacoeconomics
Pharmacoeconomics
preetidharapur
Principles of Pharmacoeconomics
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...
Aasritha William
Whereas the number and quality of economic evaluations of CAM have increased in recent years and more CAM therapies have been shown to be of good value, the majority of CAM therapies still remain to be evaluated
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
home
Pharmacoeconomics , pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioology
Divya singh
Formulation and Evaluation Study on Herbal Toothpaste
pharmacoeconomic_models.pdf
pharmacoeconomic_models.pdf
KRIMSExamination
Pharmacoeconomics
Pharmacoeconomics5-WPS Office.pdf
Pharmacoeconomics5-WPS Office.pdf
Sudipta Roy
Accounting and Medicine: An Exploratory Investigation into Physicians’ Attitudes Toward the Use of Standard Cost-Accounting Methods in Medicine Greg M. Thibadoux Marsha Scheidt Elizabeth Luckey ABSTRACT. Research studies demonstrate wide varia- tion in how physicians diagnose and treat patients with similar medical conditions and suggest that at least some of the variation reflects inefficiencies and unnecessary medical costs. Health care researchers are actively exam- ining ways to reduce variations in practice through standardization of medicine to reduce the cost of treat- ment and ensure the quality of outcomes. The most widely accepted form of this standardization is Evidence Based Best Practices (EBBP). Furthermore, financial health care providers such as hospitals and managed care organizations are investigating methods to tie resource usage to medical protocols in their efforts to monitor and control health care costs. Such proposals are contentious because they report on physicians’ medical practice behaviors (such as the number of tests ordered, use of specific therapies, etc.) and such reports could potentially be used to influence their clinical behaviors. The intent of this exploratory study was to examine physicians’ perceptions about linking a standard costing system to EBBP guidelines. The authors interviewed nine practic- ing physicians asking each physician to respond to the question, ‘As a physician working in a hospital environ- ment, what are your reactions to and concerns with combining standard costing techniques with EBBP?’ The interviews were in-depth and free form in nature. The physicians’ responses were recorded and analyzed using Grounded Theory Methodology. Using this methodol- ogy the field data was categorized into two major themes. The most important theme centered on ethics and the second theme was concerned with the implementation and use of a standard cost system in regard to EBBP. If physicians’ worries about ethical dilemmas and imple- mentation issues are not resolved, then it is likely that doctors would be unwilling to participate in any efforts to develop or use a standard cost-reporting system in med- icine. While this study was exploratory in nature, it should provide future guidance to accountants, health care researchers and health care providers about physi- cians’ issues with the use of standard costing methods in medicine. KEY WORDS: diagnostic related groups (DRGs), evidence based best practices (EBBP), grounded theory methodology, health care ethics, physician practices Introduction Healthcare costs in the United States have been rising at an alarming rate over the last several dec- ades, outpacing the Consumer Price Index. Cur- rently, nearly 16% of the Gross Domestic Product (GDP) is spent on health care (Kolata, 2006), and it is projected to rise 7.3% annually for the next dec- ade. By 2013 health care spending is projected to be Gr.
Accounting and Medicine An ExploratoryInvestigation into .docx
Accounting and Medicine An ExploratoryInvestigation into .docx
nettletondevon
Similar a Pharmacoeconomics1
(20)
Outcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics1
Pharmacoeconomics1
Pharmaconomics
Pharmaconomics
Pharmacoeconomics.ppt
Pharmacoeconomics.ppt
Pharmacoeconomics STUDY
Pharmacoeconomics STUDY
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics
Pharmacoeconomics ppt.
Pharmacoeconomics ppt.
Pharmacoeconomics
Pharmacoeconomics
PHARMACOECONOMICS.pptx
PHARMACOECONOMICS.pptx
Pharmacoeconomis
Pharmacoeconomis
Pharmacoeconomis
Pharmacoeconomis
Pharmacoeconomics
Pharmacoeconomics
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Pharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioology
pharmacoeconomic_models.pdf
pharmacoeconomic_models.pdf
Pharmacoeconomics5-WPS Office.pdf
Pharmacoeconomics5-WPS Office.pdf
Accounting and Medicine An ExploratoryInvestigation into .docx
Accounting and Medicine An ExploratoryInvestigation into .docx
Más de jinender16
ISPOR
ISPOR
jinender16
Poster at ISPOR annual meeting 2008
Poster
Poster
jinender16
Seminar in second semester
Seminar Jinender
Seminar Jinender
jinender16
APhA poster on Medication Therapy Management
APha Poster
APha Poster
jinender16
Patient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To Physicians
jinender16
Singapore
Singapore
jinender16
Pseudoephedrine
Pseudoephedrine
jinender16
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
jinender16
Poster Jinender
Poster Jinender
jinender16
Más de jinender16
(9)
ISPOR
ISPOR
Poster
Poster
Seminar Jinender
Seminar Jinender
APha Poster
APha Poster
Patient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To Physicians
Singapore
Singapore
Pseudoephedrine
Pseudoephedrine
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Poster Jinender
Poster Jinender
Pharmacoeconomics1
1.
2.
3.
4.
VALUE Health Outcome
Cost
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Descargar ahora